Imurel (Azathioprine)

Azathioprine is converted inside cells to 6‑mercaptopurine, which blocks the synthesis of purine nucleotides needed for DNA and RNA production. This inhibition limits the proliferation of activated T‑ and B‑lymphocytes, leading to reduced cytokine release and antibody formation, which collectively suppresses immune‑mediated inflammation and graft rejection.

The dosage of Imurel is individualized by the prescribing physician based on the patient’s condition, body weight, renal and hepatic function, and response to therapy. The prescriber determines the starting dose and any subsequent adjustments, and patients should follow the exact regimen provided on the prescription label.

Azathioprine is classified as a pregnancy‑category drug with limited data; it may be used only when the potential benefit outweighs the risk to the fetus. Breastfeeding is generally not recommended because the drug can be excreted in milk. Decisions should be made in consultation with a healthcare professional.

To request Imurel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including any required cold‑chain handling—and assistance with import documentation.

Compared with calcineurin inhibitors such as cyclosporine, azathioprine offers oral administration and a different toxicity profile, with less nephrotoxicity but a higher risk of bone‑marrow suppression. It is often used in combination regimens or when patients cannot tolerate alternative agents, providing a valuable option for long‑term maintenance therapy.

Imurel tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

Imurel is taken orally, usually with food or a glass of water to reduce gastrointestinal irritation. The tablet should be swallowed whole and not split, crushed, or chewed unless specifically instructed by a healthcare provider. Dosing times are typically consistent each day to maintain stable blood levels.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, significant hepatotoxicity, opportunistic infections, and a possible increased incidence of certain cancers such as lymphomas. Patients should be monitored regularly with blood tests, and any signs of infection, jaundice, or abnormal bleeding require immediate medical attention.

Individuals with known hypersensitivity to azathioprine or any of its components, those with severe liver disease, active uncontrolled infections, or a documented deficiency of thiopurine methyltransferase (TPMT) should avoid Imurel. Pregnant or breastfeeding women should only use it when clearly indicated and under close medical supervision.